par John R. Fischer
, Senior Reporter | September 04, 2020
The Centers for Medicare and Medicaid Services (CMS) has proposed a new rule that would enable medical devices approved under the FDA's "breakthrough" designation to be covered by Medicare immediately, effectively eliminating delays in patient access.
The move would permit Medicare to cover eligible breakthrough devices the FDA has approved for use in 2019 and 2020, thereby allowing Medicare beneficiaries to use them for life-threatening illnesses and conditions, according to Policy and Medicine
, a publication by Rockpointe Corporation.
“Too often, innovative devices are approved by the FDA but aren’t covered by Medicare until sufficient evidence has been collected,” said Patrick Hope, executive director of MITA, in a statement. “This creates a ‘Catch-22’ scenario in which, without adequate coverage or reimbursement, access to an FDA-approved treatment or therapy is limited to only those who can afford to pay out-of-pocket. This results in a reduced ability to collect the same data needed to support reimbursement.”
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
A breakthrough device must provide more effective treatment or diagnosis for either a life-threatening or irreversibly debilitating human disease or condition. It must also at least be designated a “breakthrough” technology, or offer a treatment option when no other cleared or approved alternatives exist, reports Policy and Medicine.
Qualifying devices would be covered nationally under Medicare Coverage of Innovative Technology (MCIT) for four years to demonstrate evidence of their value. During this time, private healthcare insurers called Medicare Administrative Contractors (MACs) would judge the reasonableness and necessity for using the technologies in specific claims. While a device is reasonable and necessary generally, it does not mean that it is reasonable and necessary in all circumstances, according to CMS.
After the four years are up, manufacturers can either seek local coverage determinations (LCD) or a national coverage determination (NCD) for qualifying devices. Those interested in pursuing an NCD are expected to submit a request for it during the third year of MCIT coverage. MCIT-covered devices would either receive an affirmative NCD, a negative NCD, or non-coverage; or MAC discretion through LCDs or claim-by-claim decisions.
Manufacturers of novel technologies would be able to opt into MCIT by notifying CMS of its intention to use the pathway. Those interested can do so by emailing CMS, which would then coordinate with the FDA and the manufacturer to start coverage once the breakthrough device is FDA market authorized. Manufacturers are still, however, responsible for obtaining the appropriate codes for their solutions.